Cytek Biosciences, Inc.
CTKB
$4.81
$0.153.22%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 48.14M | 44.14M | 62.14M | 52.29M | 45.60M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 48.14M | 44.14M | 62.14M | 52.29M | 45.60M |
| Cost of Revenue | 22.60M | 22.88M | 29.26M | 24.74M | 21.74M |
| Gross Profit | 25.54M | 21.25M | 32.89M | 27.55M | 23.87M |
| SG&A Expenses | 30.00M | 30.11M | 29.52M | 27.79M | 25.67M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 62.34M | 62.60M | 67.74M | 61.49M | 56.23M |
| Operating Income | -14.20M | -18.46M | -5.59M | -9.19M | -10.62M |
| Income Before Tax | -11.64M | -17.37M | -4.03M | -7.77M | -6.78M |
| Income Tax Expenses | 515.00K | 1.49M | 40.05M | -2.29M | -1.19M |
| Earnings from Continuing Operations | -12.16M | -18.87M | -44.08M | -5.48M | -5.58M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.16M | -18.87M | -44.08M | -5.48M | -5.58M |
| EBIT | -14.20M | -18.46M | -5.59M | -9.19M | -10.62M |
| EBITDA | -12.19M | -16.60M | -3.70M | -7.27M | -8.73M |
| EPS Basic | -0.09 | -0.15 | -0.34 | -0.04 | -0.04 |
| Normalized Basic EPS | -0.06 | -0.08 | -0.02 | -0.04 | -0.03 |
| EPS Diluted | -0.09 | -0.15 | -0.34 | -0.04 | -0.04 |
| Normalized Diluted EPS | -0.06 | -0.08 | -0.02 | -0.04 | -0.03 |
| Average Basic Shares Outstanding | 129.46M | 128.70M | 128.17M | 127.55M | 126.93M |
| Average Diluted Shares Outstanding | 129.46M | 128.70M | 128.17M | 127.55M | 126.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |